Article Information
History
- April 5, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Lucie Loyal1,2,
- Julian Braun1,2,†,
- Larissa Henze1,2,†,
- Beate Kruse1,2,†,
- Manuela Dingeldey1,2,†,
- Ulf Reimer3,†,
- Florian Kern3,4,†,
- Tatjana Schwarz5,6,†,
- Maike Mangold1,2,
- Clara Unger1,2,
- Friederike Dörfler1,
- Shirin Kadler1,7,
- Jennifer Rosowski1,7,
- Kübrah Gürcan1,7,
- Zehra Uyar-Aydin1,7,
- Marco Frentsch8,9,
- Florian Kurth10,11,
- Karsten Schnatbaum3,
- Maren Eckey3,
- Stefan Hippenstiel10,
- Andreas Hocke10,
- Marcel A. Müller6,
- Birgit Sawitzki12,
- Stefan Miltenyi13,
- Friedemann Paul14,15,
- Marcus A. Mall16,
- Holger Wenschuh3,
- Sebastian Voigt17,
- Christian Drosten5,6,
- Roland Lauster1,7,‡,
- Nils Lachman18,‡,
- Leif-Erik Sander10,‡,
- Victor M. Corman5,6,‡,
- Jobst Röhmel16,‡,
- Lil Meyer-Arndt1,2,14,15,19,‡,
- Andreas Thiel1,2,‡,*,
- Claudia Giesecke-Thiel20,‡,*,
- the Charité Corona Cross Study Group
- 1Si-M / “Der Simulierte Mensch” a science framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany
- 2Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies, Berlin (BCRT), Germany
- 3JPT Peptide Technologies GmbH, Berlin, Germany
- 4Brighton and Sussex Medical School, Department of Clinical and Experimental Medicine, Brighton, UK
- 5Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
- 6Charité - Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany
- 7Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany
- 8Charité - Universitätsmedizin Berlin, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany
- 9Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Therapy-Induced Remodeling in Immuno-Oncology, Berlin, Germany
- 10Charité - Universitätsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany
- 11Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & i. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 12Charité - Universitätsmedizin Berlin, Institute of Medical Immunology, Berlin, Germany
- 13Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany
- 14Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin, Germany
- 15Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology, NeuroCure Clinical Research Center, Berlin, Germany
- 16Department of Pediatric Pulmonology, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
- 17Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany
- 18Charité - Universitätsmedizin Berlin, Institute for Transfusion Medicine, Tissue Typing Laboratory, Berlin, Germany
- 19Charité - Universitätsmedizin Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany
- 20Max Planck Institute for Molecular Genetics, Berlin, Germany
- ↵*Correspondence to: andreas.thiel{at}charite.de, giesecke{at}molgen.mpg.de
↵† These authors contributed equally to this work.
Posted April 05, 2021.
Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
